The Global Insulin Pump Market achieved a valuation of $5.90 Billion in 2024 and is anticipated to exceed $14.49 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 8.55% during the ...

Among patients with type-2 diabetes (T2D) requiring insulin therapy, automated insulin delivery (AID) resulted in a greater ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

Another AID system, the Omnipod 5 ... in a 2:1 ratio to receive the AID with Tandem’s t:slim X2 insulin pump with Control-IQ+ technology in conjunction with a Dexcom G6 CGM, or to continue ...

Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes.

Beck and colleagues from the JAEB Center for Health Research, Tampa, Florida, USA, highlight the rapid onset of action of inhaled Technosphere Insulin (TI, Afrezza) compare ...

A landmark international study involving patients and researchers at St. Joseph’s Health Care London shows automated insulin ...

Automated insulin delivery systems have demonstrated benefits ... which received the t:slim X2 insulin pump with Control-IQ+ technology and a Dexcom G6 sensor, or the control group, which ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes using an automated ...

In a terrifying new report from Zurich-based cybersecurity Scip AG, experts revealed how they were easily able to hijack ...

The AID system used in the study was Tandem Diabetes Care's t:slim X2 insulin pump with Control-IQ+ technology, used in conjunction with a Dexcom G6 CGM sensor that can be used with NovoLog or ...